- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03552471
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Study Overview
Status
Conditions
- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
- Folate Receptor Alpha Positive
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Uterine Corpus Carcinoma
- Recurrent Uterine Serous Carcinoma
- Recurrent Uterine Carcinosarcoma
- Platinum Resistant Ovarian Cancer
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the recommended phase II dose (RPTD) of combination mirvetuximab soravtansine and rucaparib camsylate (rucaparib) in patients with recurrent endometrial, epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.
SECONDARY OBJECTIVES:
I. To determine the safety and tolerability of combination mirvetuximab soravtansine and rucaparib in study patients.
II. To explore the objective antitumor activity (complete and partial response) of combination mirvetuximab soravtansine and rucaparib as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria in the study population.
III. To measure the progression free survival. IV. To evaluate the pharmacokinetics of mirvetuximab soravtansine and rucaparib in combination.
EXPLORATORY OBJECTIVES:
I. Explore additional biomarkers of response. II. Explore mutation characteristics and frequency with treatment response. III. Evaluate if companion diagnostics can be optimized by combining loss of heterozygosity (LOH) score and level of folate receptor a (FR-alpha) expression, and possible additional predictors of response.
IV. Explore mechanisms of secondary resistance to treatment.
OUTLINE: This is a dose escalation study.
Participants receive mirvetuximab soravtansine intravenously (IV) on day 1 and rucaparib orally (PO) twice daily (BID) on days 1 through 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed up at 30 days and then every 3 months for up to a year.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients must have histologically or cytologically confirmed:
- Recurrent endometrial cancer (all histologies, including carcinosarcoma)
Recurrent ovarian, primary peritoneal (female only), or fallopian tube cancer
- all histologies except low grade serous or clear cell carcinoma unless the patient has a known somatic or germline breast cancer (BRCA) mutation disease that is metastatic and for which standard curative measures do not exist or are no longer effective
- For the dose escalation portion of the trial, patients with available therapies known to confer clinical benefit (platinum sensitive ovarian cancer) must be excluded
- For the dose expansion cohort, patients with recurrent endometrial cancer, recurrent BRCA mutated ovarian cancer (except first-recurrence platinum sensitive ovarian cancer), and platinum resistant ovarian cancer are eligible
- Patients must have confirmation of folate receptor-a (FR-alpha) positivity by immunohistochemistry (IHC) (? 25% of tumor staining at ? 2 + intensity) on archival tissue or recent biopsy.
Patients must be willing and able to undergo tissue biopsy for research
- If tumor tissue obtained from the biopsy is deemed inadequate, and the patient is unwilling or unable to have another biopsy, the patient may be considered for enrollment if archival tumor tissue is provided and deemed of adequate quality; this must occur prior to any treatment with rucaparib or mirvetuximab soravtansine
- If biopsy is deemed unsafe to attempt or to perform, and if archival tumor tissue is available and deemed of adequate quality, the patient may enroll on trial
- Biopsy must be of solid tumor tissue; ascites is not acceptable
- Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
Prior therapy:
- Patients may have received unlimited prior treatment for the dose escalation part
- For the expansion cohort patients must have ? 4 prior lines of chemotherapy
- Hormonal therapy does not count towards total lines of therapy
- Maintenance therapy is considered part of the preceding regimen if one or more of the same drugs are continued
- Neoadjuvant and adjuvant chemotherapy are considered one regimen if they are a continuation of the same regimen with interval debulking surgery
- Prior treatment with folate receptor (FR) targeting investigational agents is allowed for dose escalation provided that such treatment was not discontinued due to adverse events; prior FR-targeting investigational agents are not allowed for patients in the expansion cohort
- Patients with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer must have received at least one platinum-based chemotherapy regimen
- Patients who have received prior taxanes, including weekly taxanes are allowed
Patients previously treated with a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor may be enrolled provided:
- PARP inhibitor was not the most recent treatment
- PARP inhibitor treatment was discontinued > 6 months before the first planned dose of rucaparib
Time from prior therapy:
- Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter (6 weeks for nitrosoureas or mitomycin C)
- Hormonal therapy is not considered anti-neoplastic therapy
- Radiotherapy: wide-field radiotherapy (e.g. > 30% of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment
- Eastern cooperative oncology group (ECOG) performance status ? 1 and life expectancy > 12 weeks
- Leukocytes ? 2,000/mcL
- Absolute neutrophil count ? 1,500/mcL
- Platelets ? 100,000/mcL
- Hemoglobin ? 9.0 g/dL
- Total bilirubin ? 1.5 x upper limit of normal (ULN) (Patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin < 3.0 x ULN)
- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/ alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) ? 2.5 ? institutional upper limit of normal
- Creatinine ? 1.5 x upper limit of normal (ULN) OR creatinine clearance ? 50 mL/min/1.73 m^2 (using Cockroft Gault Formula) for patients with creatinine levels above institutional normal
- Corrected QT (QTc) interval ? 470 msec on screening electrocardiogram (ECG)
- Major surgery must have been completed ? 4 weeks prior to starting treatment day 1; patient must be sufficiently recovered and stable from surgery prior to treatment day 1
- Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; patients must have a negative pregnancy test (urine and/or serum) prior to enrollment
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients with available therapies known to confer clinical benefit (platinum sensitive recurrent ovarian cancer) must be excluded from the dose escalation portion
- For the dose expansion cohort patients with first-recurrence platinum-sensitive ovarian cancer must be excluded
- Patients who have had chemotherapy or radiotherapy within 4 weeks or five half-lives whichever is shorter (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual drug related toxicities > grade 1) except for alopecia and grade 2 fatigue
- Patients who are receiving any other investigational agents
- Primary platinum refractory disease (disease progression on first platinum treatment or recurrence within 3 months of completing first platinum regimen)
- Patients with clear cell or low grade ovarian cancer unless the patient has a known germline or somatic breast cancer (BRCA) mutation or a mutation in another homologous recombination gene
- Any known gastrointestinal disorder determined by the investigator that interferes with the absorption of rucaparib
- Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids; patients with treated brain metastases are eligible as long as they completed prior brain radiation therapy more than 14 days prior to first dose of study therapy, are not experiencing seizures and are not receiving steroids for symptomatic brain metastases (for at least 7 days prior to first dose of study treatment)
- History of leptomeningeal carcinomatosis
- Subjects with a known history of uncontrolled seizures
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to rucaparib, mirvetuximab soravtansine or monoclonal antibodies
Uncontrolled inter-current illness including, but not limited to:
- Ongoing or active infection (requiring IV antibiotics within 2 weeks of study enrollment)
- Symptomatic/uncontrolled congestive heart failure (New York heart association > class II)
- Unstable angina pectoris
- Recent myocardial infarction (< 6 months)
- Uncontrolled cardiac arrhythmia
- Uncontrolled hypertension (? Common Terminology Criteria for Adverse Events [CTCAE] v4.03 grade 3)
- Prior history of hypertensive crisis or hypertensive encephalopathy
- Hemorrhagic or ischemic stroke < 6 months
- Clinically-significant vascular disease (e.g. aortic aneurysm, or dissecting aneurysm), severe aortic stenosis clinically significant peripheral vascular disease, or ? grade 3 cardiac toxicity following prior chemotherapy
- Interstitial lung disease (ILD)
- Active peptic ulcer disease or gastritis interfering with the absorption of rucaparib
- Active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C
- Active varicella zoster infection, cytomegalovirus infection, or history of tuberculosis
- Psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
- Active or chronic corneal disorder, including but not limited to the following: Sjogren?s syndrome, Fuchs corneal dystrophy (requiring treatment), history of corneal transplantation, active herpetic keratitis, and also active ocular conditions requiring on-going treatment/monitoring such as wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, presence of papilledema, acquired monocular vision, and any preexisting active conjunctival disease
- History of neurological conditions that would confound assessment of treatment-emergent neuropathy
- History of multiple sclerosis or other demyelinating disease and/or Eaton-Lambert syndrome (para-neoplastic syndrome)
- Previous clinical diagnosis of non-infectious pneumonitis
- History or evidence of thrombotic disorders within 6 months before first study treatment unless stable on anticoagulation for > 3 months
- Required used of folate-containing supplements (e.g. folate deficiency)
- Has a known additional malignancy that is progressing or required active treatment within 3 years of first dose of study treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or other in situ cancers
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with rucaparib and mirvetuximab soravtansine
- Women who are breastfeeding
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
- Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (mirvetuximab soravtansine, rucaparib)
Participants receive mirvetuximab soravtansine IV on day 1 and rucaparib PO BID on days 1 through 21.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given IV
Other Names:
Correlative studies
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended phase II dose (RPTD) of mirvetuximab soravtansine and rucaparib camsylate in combination
Time Frame: At the end of Cycle 1 (each cycle 15 days)
|
based on DLT and toxicity
|
At the end of Cycle 1 (each cycle 15 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse effects graded according to CTCAE v. 4.0
Time Frame: while on study drug and up to 30 days after (through study treatment completion, an average of 1 year)
|
Will be evaluated descriptively using frequencies and percentages
|
while on study drug and up to 30 days after (through study treatment completion, an average of 1 year)
|
Objective anti-tumor activity (complete and partial response) of mirvetuximab soravtansine and rucaparib in combination
Time Frame: Up to 1 year after completion of study treatment
|
Response rate determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
|
Up to 1 year after completion of study treatment
|
Progression-free survival
Time Frame: From start of treatment up to 1 year after completion of study treatment
|
Progression-free survival determined by Kaplan-Meier curves.
|
From start of treatment up to 1 year after completion of study treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of mirvetuximab soravtansine and rucaparib in combination Cmax trough concentrations
Time Frame: predose and post dose at selected times
|
Pharmacokinetics determined by analysis of collected blood samples
|
predose and post dose at selected times
|
Collaborators and Investigators
Investigators
- Principal Investigator: Floor Backes, MD, Ohio State University Comprehensive Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Neoplasms, Complex and Mixed
- Sarcoma
- Cystadenocarcinoma
- Neoplasms, Cystic, Mucinous, and Serous
- Carcinoma
- Recurrence
- Carcinosarcoma
- Mixed Tumor, Mullerian
- Cystadenocarcinoma, Serous
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Poly(ADP-ribose) Polymerase Inhibitors
- Immunoconjugates
- Rucaparib
- Maytansine
- Mirvetuximab soravtansine
Other Study ID Numbers
- OSU-18007
- NCI-2018-00438 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BRCA1 Gene Mutation
-
Rabin Medical CenterUnknownBRCA1 Gene Mutation | BRCA2 Gene MutationIsrael
-
Ohio State University Comprehensive Cancer CenterRecruitingBRCA1 Gene Mutation | BRCA2 Gene MutationUnited States
-
University of California, San FranciscoAmerican Cancer Society, Inc.CompletedBRCA1 Gene Mutation | BRCA2 Gene MutationUnited States
-
Pamela MunsterNational Cancer Institute (NCI)Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene MutationUnited States
-
University of California, San FranciscoGlaxoSmithKlineRecruitingMetastatic Solid Tumor | BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene MutationUnited States
-
Rabin Medical CenterCompletedBRCA1 Gene Mutation | BRCA2 Gene MutationIsrael
-
University Medical Center NijmegenRecruitingOvarian Cancer | BRCA1 Gene Mutation | BRCA2 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene MutationNetherlands, United States, Belgium, Norway, Poland, Italy, Australia, Mexico, Brazil, Sweden, Uruguay
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6... and other conditionsUnited States
-
Marc Dall'Era, MDNational Cancer Institute (NCI); Janssen, LPRecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditionsUnited States
-
Beth Israel Deaconess Medical CenterJohns Hopkins University; Dana-Farber Cancer Institute; AstraZenecaActive, not recruitingMetastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)United States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States